Endlyz Therapeutics is a biotechnology company pioneering disease-modifying therapies that will restore lysosomal function and neuronal health in Parkinson’s disease and other neurodegenerative diseases. We are targeting lysosomal transporters ATP13A2 and ATP10B, which are are key for maintaining lysosomal homeostasis. Founded and incubated by the Dementia Discovery Fund (DDF), Endlyz is backed by Oxford Science Enterprises (OSE), AbbVie Ventures, Parkinson’s UK, and the Centre for Drug Design and Discovery (CD3). The Company is raising for $30M Series A to advance its lead programme into the clinic and expand pipeline.

Endlyz has a UK and U.S. presence with Endlyz UK Ltd being a wholly owned subsidiary of Endlyz Therapeutics, Inc.